- Home
- ALT vs CLW Comparison
ALT vs CLW Comparison
Compare ALT & CLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALT
- CLW
- Stock Information
- Founded
- ALT 1997
- CLW 2005
- Country
- ALT United States
- CLW United States
- Employees
- ALT N/A
- CLW N/A
- Industry
- ALT Biotechnology: Pharmaceutical Preparations
- CLW Paper
- Sector
- ALT Health Care
- CLW Basic Materials
- Exchange
- ALT Nasdaq
- CLW Nasdaq
- Market Cap
- ALT 472.3M
- CLW 481.8M
- IPO Year
- ALT N/A
- CLW N/A
- Fundamental
- Price
- ALT $6.43
- CLW $27.30
- Analyst Decision
- ALT Strong Buy
- CLW Buy
- Analyst Count
- ALT 7
- CLW 1
- Target Price
- ALT $20.83
- CLW $37.00
- AVG Volume (30 Days)
- ALT 2.0M
- CLW 291.9K
- Earning Date
- ALT 02-27-2025
- CLW 02-13-2025
- Dividend Yield
- ALT N/A
- CLW N/A
- EPS Growth
- ALT N/A
- CLW 85.68
- EPS
- ALT N/A
- CLW 11.70
- Revenue
- ALT $52,000.00
- CLW $1,383,600,000.00
- Revenue This Year
- ALT N/A
- CLW $14.27
- Revenue Next Year
- ALT N/A
- CLW N/A
- P/E Ratio
- ALT N/A
- CLW $2.41
- Revenue Growth
- ALT N/A
- CLW N/A
- 52 Week Low
- ALT $5.28
- CLW $23.97
- 52 Week High
- ALT $14.84
- CLW $57.13
- Technical
- Relative Strength Index (RSI)
- ALT 42.82
- CLW 39.33
- Support Level
- ALT $6.06
- CLW $25.38
- Resistance Level
- ALT $7.10
- CLW $32.55
- Average True Range (ATR)
- ALT 0.36
- CLW 1.19
- MACD
- ALT 0.03
- CLW -0.44
- Stochastic Oscillator
- ALT 33.33
- CLW 26.78
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and selling of private label tissue, paperboard, and pulp-based products. The company has two reportable segments namely the consumer products segment which manufactures and sells a complete line of at-home tissue products as well as AFH products. The pulp and paperboard segment manufactures and markets bleached paperboard for the high-end segment of the packaging industry as well as offers services that include custom sheeting, slitting and cutting of paperboard. It generates maximum revenue from Pulp and Paperboard segment. Geographically, it derives maximum revenue from the United States.